Journal of Diagnostics Concepts & Practice ›› 2017, Vol. 16 ›› Issue (06): 622-626.doi: 10.16150/j.1671-2870.2017.06.012

• Original articles • Previous Articles     Next Articles

Intracranial solitary fibrous tumor/hemangiopericytoma: a clinicopathologic study of 20 cases with review of literature

ZHU Peipei1, ZOU Jue2, *, CHEN Jun1, XU Rongrong3, YAN Hongzhu2   

  1. 1. Department of Pathology, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China, 200003;
    2. Department of Pathology, Seventh People’s Hospital of Shanghai University of Tradional Chinese Medicine, Shanghai 200137, China;
    3. Department of Pathology, Wuxi Sencond People's Hospital, Jiangsu Wuxi 214001, China
  • Received:2017-02-10 Online:2017-12-25 Published:2017-12-25

Abstract: Objective: To study the clinicopathologic features, diagnosis, differential diagnosis and prognosis of intracranial solitary fibrous tumor/hemangiopericytoma(SFT/HPC). Methods: A total of 20 cases of intracranial SFT/HPC were enrolled in this study. The clinical data, pathologic characteristics and immunophenotype were studied and relevant literatures were reviewed. Results: Of these patients, 12 cases were male and 8 were female, with an average age of 48.45 years. Seven cases received meningioma resection 6-19 years before. According to the latest 2016 WHO classification, there were 1 case of grade Ⅰ, 13 cases of grade Ⅱ and 6 cases of grade Ⅲ. Immunohisochemically, tumor cells of all specimen were positive for vimentin, bcl-2, CD34 and STAT6, and were negative for EMA, AE1/AE3, S-100, CD31 and factor Ⅷ. The cells of grade Ⅰ case were strong and diffusely positive for CD34, while the cells of grade Ⅱ and grade Ⅲ cases had weak expression and patchy distribution of CD34. Ki-67 proliferation index ranged from 3% to 30%. Fifteen of the 20 patients were followed-up for 5 months to 19 years. During this period, 5 cases had disease recurrence, and 13 received postoperative radiotherapy, while 2 case did not receive any therapy. Up to March 2017, all cases were survived. Conclusions: According to the latest releas from WHO, SFT and HPC are classified as the same type of tumor, and immunohistochemistry staining of CD34 and ki-67 may be useful to grading and differential diagnosis of SFT/HPC.

Key words: Solitary fibrous tumor/hemangiopericytoma, Immunohistochemistry, Differential diagnosis

CLC Number: